Lycopene used as Anti-inflammatory Nanodrug for the Treatment of Rheumathoid Arthritis: Animal assay, Pharmacokinetics, ABC Transporter and Tissue Deposition

Publication date: April 2020Source: Colloids and Surfaces B: Biointerfaces, Volume 188Author(s): Vivian Meira Moia, Filipe Leal Portilho, Tatiana Almeida Pádua, Luana Barbosa Corrêa, Eduardo Ricci-Junior, Elaine Cruz Rosas, Luiciana Magalhaes Rebelo Alencar, Francisco Savio Mendes Sinfronio, Angelina Sampson, Surtaj Hussain Iram, Frank Alexis, Maria dasGraccedilasMuller de OliveiraHenriques, Ralph Santos-OliveiraAbstractLycopene is a carotenoid drug that has demonstrated several properties, including antioxidant and anti-inflammatory activity. The absorption in human body is very low (10–30 % only). In order to increase the bioavailability, lycopene nanoemulsion was formulated and characterized (atomic force microscopy, thermogravimetric analysis dynamic light scattering and differential scanning calorimetry). Also in vitro assay to evaluate the at-binding with MPR1 was performed. Finally, in vivo assay in animals inducted with rheumathoid arthritis were performed. The results showed that the formulated nanolycopene had superior efficacy when compared with the conventional lycopene (not nano-formulated) in inducted animals (rheumatoid arthritis). The results support the use of nanolycopene as an anti-inflammatory agent for rheumatoid arthritis therapy.Graphical abstract
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research